Filing and period
Source mismatch: The supplied filing is MEI Pharma, Inc.’s unaudited Form 10-Q for the quarter ended December 31, 2023 (filed February 13, 2024), not a Lite Strategy, Inc. filing for 2022 Q2. The summary below covers the filing actually provided.
MEI Pharma is a clinical-stage oncology company. Its stated active candidates are voruciclib and ME-344. The company discontinued zandelisib development globally with Kyowa Kirin (KKC) and regained global rights, subject to limited compassionate-use provisions.
Financial performance and condition
Amounts below are in U.S. dollars; financial statement figures are unaudited. The filing reports no product gross-margin measure.
| Metric | Three months ended Dec. 31, 2023 | Three months ended Dec. 31, 2022 | Six months ended Dec. 31, 2023 | Six months ended Dec. 31, 2022 |
|---|---|---|---|---|
| Revenue | $0 | $32.7 million | $65.3 million | $41.5 million |
| Operating expenses | $11.9 million | $23.8 million | $21.9 million | $50.8 million |
| Operating income (loss) | $(11.9) million | $8.9 million | $43.4 million | $(9.3) million |
| Net income (loss) | $(11.1) million | $10.3 million | $45.3 million | $(6.4) million |
| Net income (loss) per share, basic and diluted | $(1.66) | $1.54 | $6.80 | $(0.96) |
- Revenue and earnings comparability: Six-month 2023 revenue included $64.5 million of deferred KKC collaboration revenue recognized in the September 2023 quarter upon termination of the agreement. This was noncash and nonrecurring; it drove six-month operating and net income despite ongoing operating cash use. The December quarter had no revenue.
- Cash and investments: At December 31, 2023, cash and cash equivalents were $5.2 million and short-term U.S. government investments were $54.3 million, totaling $59.5 million, versus $100.7 million at June 30, 2023.
- Cash flow: Operating activities used $29.5 million in the six months, compared with $29.1 million in the prior-year period. Investing activities provided $29.5 million, primarily reflecting net investment maturities; financing activities used $11.7 million for the special dividend. Cash declined $11.7 million over the six months.
- Liquidity and obligations: Current assets were $66.2 million and current liabilities $8.0 million. Total liabilities were $19.1 million, including $12.0 million in operating lease liabilities. The filing does not report financial borrowings. Remaining minimum lease payments were $15.2 million before discounting and variable costs.
- Margins: No gross margin is presented. Operating and net margins are not informative as a measure of ongoing performance given the large, one-time KKC revenue recognition.
Material changes and management commentary
- Quarterly revenue fell to zero from $32.7 million a year earlier, reflecting the KKC agreement’s termination and recognition of its remaining deferred revenue in the prior quarter. Six-month revenue rose year over year because that $64.5 million was recognized.
- Quarterly R&D expense declined to $3.9 million from $15.3 million, principally due to zandelisib discontinuation and workforce reductions; ME-344 clinical and manufacturing costs increased. Six-month R&D was $7.4 million versus $34.8 million.
- Quarterly G&A decreased to $8.0 million from $8.5 million, while legal costs related to the Cooperation Agreement partially offset savings. The company recorded $1.1 million of investor-related fee reimbursements in G&A during the six-month period.
- On December 6, 2023, MEI paid a $1.75-per-share special dividend totaling $11.7 million under its Cooperation Agreement with Anson Funds and Cable Car Capital. A further return of capital of up to $9.33 million may be considered if specified ME-344 trial conditions occur; it requires Board approval and was not declared or accrued at December 31.
- The agreement also involved director changes, appointments of investor-designated directors, and formation of a Capital Allocation Committee. The investors withdrew their consent solicitation and agreed to standstill provisions.
- Management said existing cash and investments should fund operations for at least 12 months from issuance of the financial statements and through anticipated clinical readouts. It expects operating losses and negative operating cash flows for the foreseeable future and expects to seek future capital through equity, debt, licenses, or partnerships; additional financing is not assured.
Clinical outlook, risks, and contingencies
- Voruciclib: Phase 1 monotherapy dose escalation/expansion was completed in 40 patients. The company reported tolerability up to 200 mg on an intermittent schedule, with no dose-limiting toxicities on that schedule. Combination testing with venetoclax in relapsed/refractory AML is ongoing; data were expected in the first calendar quarter of 2024. These are company-reported early clinical observations, not evidence of established efficacy.
- ME-344: A Phase 1b study with bevacizumab in relapsed colorectal cancer is ongoing. Data from the first cohort of approximately 20 patients were expected in the first half of calendar 2024. The Cooperation Agreement’s potential additional capital return depends in part on trial endpoints or the Board’s decision on a second cohort.
- Key risks: Clinical-stage drug development, uncertain trial outcomes and regulatory approval, patient enrollment, manufacturing and third-party dependencies, intellectual-property protection, competition, and the need for additional capital. Management noted that trial costs and timelines are uncertain.
- Other matters: Management reported no material pending litigation at December 31, 2023 and no material changes to the risk factors in its prior annual report. Disclosure controls were assessed as effective; no material change in internal control over financial reporting was reported. The filing identifies no material impact from macroeconomic conditions on the period’s financial statements.
Investor verification points
- Confirm the filing identity and reporting period: the provided document is MEI Pharma’s December 31, 2023 10-Q, not the company and period in the request metadata.
- Separate the $64.5 million noncash KKC termination-related revenue from recurring operating performance and cash generation.
- Check current cash use, investment maturities, and any subsequent financing or partnership activity against management’s 12-month liquidity statement.
- Verify actual voruciclib and ME-344 trial readouts, safety, enrollment, and decisions about further cohorts against the forward-looking timelines stated in the filing.
- Monitor whether the Board authorizes the potential second return of capital of up to $9.33 million and assess the effect of any further capital return on the clinical-development runway.